Hot Keywords
Tumor Microenvironment Exosomes and Extracellular Vesicles Breast Cancer Metastasis Bone Metastasis Metastatic Renal Cell Carcinoma Lymph node metastasis Mesothelioma Hematological Malignancies Thyroid Cancer Liquid Biopsies Early Diagnosis Lung Cancer Brain Tumors Lymphoma Oncolytic Virus Cervical Cancer Cancer Stem Cells

Topic: Therapy-related Myeloid Neoplasms

A special issue of Journal of Cancer Metastasis and Treatment

ISSN 2454-2857 (Online), ISSN 2394-4722 (Print)

Submission deadline: 31 Jan 2023

Guest Editor(s)

  • Valeria Visconte, PhD
    Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.

    Website | E-mail

Special Issue Introduction

Therapy-related myeloid neoplasms (t-MN) are a late result of DNA damage in the normal hematopoietic compartment triggered by cytotoxic chemotherapy and/or radiotherapy for the treatment of prior neoplasms, autoimmune diseases and solid organ transplants. The category includes therapy-related acute myeloid leukemia (t-AML), therapy-related myelodysplastic syndrome (t-MDS) and therapy-related MDS/myeloproliferative neoplasm (t-MDS/MPN). Patients with t-MN have a poor prognosis. Causes associated with the development of t-MN span from inherited genetic predisposition (germline mutations) to more recently the presence of clonal hematopoiesis of indeterminate potential at the time of treatment. Subtypes of t-MN and response to therapies depend on the type of treatment (alkylating/radiotherapy, topoisomerase II inhibitors). This special issue will focus on the late consequences of chemotherapy and/or radiation, genetics, and intrinsic and extrinsic factors contributing to the development of t-MN.

Submission Deadline

31 Jan 2023

Submission Information

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to
For Online Submission, please login at
Submission Deadline: 31 Jan 2023
Contacts: Gladys Di, Assistant Editor,

Published Articles

© 2016-2022 OAE Publishing Inc., except certain content provided by third parties